•  Evaluate how increased screening can improve pediatric and adult patient outcomes with current therapies and how those who are newly screened may be affected by approval of CFTR modulators. 
• Integrate this information into current clinical practice to more effectively advise and counsel patients, manage patient expectations, and improve quality of life for the pediatric and adult patient.
• Discuss best practices for treating infectious processes in CF patients.
• Describe how the pre-symptomatic diagnosis of children alters approach therapy.
• Detail the differences in prophylactic use of therapies vs. symptomatic care.
• Develop more efficacious individual care plans for pediatric and adult patients.
• Evaluate international disease modifying therapies that affect CFTR.
• Review the novel therapies on the horizon.
• Describe and discuss currently successful CF adherence improvement model.
• Analyze how the pending approval of CFTR modulating therapies may impact adherence.
  

Upon completion of the post-test, please take a moment to respond to our program evaluation.